The efect of Glutamine in the defense system of patients with HIV/AIDS

Not Applicable

• Conditions: A prospective study, a randomized clinical trial, carried out in patients with HIV/AIDS and with outpatient follow-up at a specialized unit in the city of Cuiabá-MT.Keyword: Glutamine, Immune System, HIV e HIV Long-Term Survivors.; D12.125.068.330; B04.820.650.589.650.350; M01.860.400

• Registration Number: RBR-77tjsw
• Lead Sponsor: niversidade Federal de Mato Grosso

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Study Start: 2018-09-18
• Last Update Posted: 29 May 2023

Recruitment & Eligibility

• Status: Data analysis completed
• Sex: Not specified
• Target Recruitment: Not specified

Inclusion Criteria

The study included patients considered to be adherent to the treatment, both men and women, between 18 and 50 years of age with positive serology for HIV/AIDS, enrolled in this unit, in regular treatment / follow-up and in the use of antiretroviral drugs (zidovudine / lamivudine and lopinavir / ritonavir) for at least two years, with Global Subjective Assessment = A (well nourished), who accepted to participate in the research with prior signature of the Informed Consent Term (TCLE)

Exclusion Criteria

Exclusion criterion were: patients who started treatment less than 2 years ago; with comorbidities; with a history of gastrointestinal tract operations; who used drugs that induced metabolic changes, as well as drug addicts and alcoholics. Also excluded were clinically severe or unstable patients, in addition to pregnant or infants; people with some mental disorder; who used glutamine or other supplement; patients with Global Subjective Evaluation B or C (moderately undernourished or severely undernourished) and patients who did not agree to participate in the study or did not sign the consent form.

Study & Design

• Study Type: Intervention
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Significant statistical difference was observed in the basal insulin dosage in the A/L-glutamine group between the first and eighth day of supplementation, given not identified in group B maltodextrin (7.1 ± 2.7 vs. 4.8 ± 2.0; p=0.023).<br>Other variables did not present significant statistical difference.;The demographic data evaluated were similar between the two groups. All patients were classified as well nourished (ASG A) according to the Global Subjective Assessment. Identical mean weight in both groups (p=0.093). For measurements of CD4 + (p=0.832) and CD8 + (p=0.974), both groups did not present statistical significance.

Secondary Outcome Measures

Name	Time	Method
Secondary outcomes are not expected